Janus Henderson Capital Funds plc - Global Life Sciences Fund Class I2 HSGDRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 21.3 | 4.3 | 8.3 | 0.4 | 8.8 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 21/11/2024 | SGD 16.12 | |
Day Change | 0.55% | |
Morningstar Category™ | Other Equity | |
ISIN | IE00BJJMRZ35 | |
Fund Size (Mil) 21/11/2024 | USD 4034.08 | |
Share Class Size (Mil) 21/11/2024 | SGD 46.16 | |
Max Initial Charge | 2.00% | |
Ongoing Charge 01/10/2022 | 1.56% |
Investment Objective: Janus Henderson Capital Funds plc - Global Life Sciences Fund Class I2 HSGD |
The Fund’s investment objective is long-term growth of capital. It pursues its objective by investing at least 80% of its net asset value in equities (also known as company shares) located anywhere in the world and selected for their growth potential. The Fund will invest at least 80% of its net asset value in companies that the relevant Sub-Investment Adviser believes have a life sciences orientation. Generally speaking, the “life sciences” relate to maintaining or improving quality of life. Thus, companies with a “life sciences orientation” include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. Such companies may also include companies that the relevant Sub-Investment Adviser believes have growth potential mainly as a result of particular products, technology, patents or other market advantages in the life sciences. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Andy Acker 01/05/2007 | ||
Daniel Lyons 31/01/2023 | ||
Inception Date 04/06/2019 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care NR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Janus Henderson Capital Funds plc - Global Life Sciences Fund Class I2 HSGD | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.62 |
UnitedHealth Group Inc | Healthcare | 6.78 |
Novo Nordisk A/S | 4.46 | |
AbbVie Inc | Healthcare | 3.79 |
AstraZeneca PLC | Healthcare | 3.52 |
Increase Decrease New since last portfolio | ||
Janus Henderson Capital Funds plc - Global Life Sciences Fund Class I2 HSGD |